Aarti Pharmalabs Limited (NSE:AARTIPHARM)
India · Delayed Price · Currency is INR 642.35
+9.10 (1.44%)
Jun 1, 2026, 3:29 PM IST
Aarti Pharmalabs Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 1,747 | 2,724 | 2,169 | 1,935 | 1,223 |
Depreciation & Amortization | 1,043 | 816.44 | 719.65 | 625.43 | 421.19 |
Other Amortization | - | 52.6 | 12.7 | - | - |
Loss (Gain) From Sale of Assets | - | - | -5.51 | 4.47 | -0.4 |
Asset Writedown & Restructuring Costs | 71.44 | - | - | - | - |
Provision & Write-off of Bad Debts | 22.54 | 12.81 | 10.68 | 15 | - |
Other Operating Activities | 804.49 | 570.38 | 475.51 | 237.64 | 223.3 |
Change in Accounts Receivable | -992.77 | -844.33 | -1,255 | -351.72 | -1,025 |
Change in Inventory | -805.65 | 552.79 | -396.64 | -1,267 | -559.92 |
Change in Accounts Payable | 702.46 | -569.13 | 433.48 | 1,302 | -718.62 |
Change in Other Net Operating Assets | 26.37 | - | - | - | - |
Operating Cash Flow | 2,619 | 3,316 | 2,164 | 2,501 | -437.04 |
Operating Cash Flow Growth | -21.00% | 53.25% | -13.50% | - | - |
Capital Expenditures | -4,094 | -4,020 | -1,556 | -1,021 | -1,412 |
Sale (Purchase) of Intangibles | 389.47 | -418.41 | -431.81 | -175.29 | - |
Investment in Securities | 125.12 | 228.34 | -188.53 | -391.23 | -0.73 |
Other Investing Activities | -728.09 | 71.47 | 30.74 | 9.77 | 24.86 |
Investing Cash Flow | -4,307 | -4,139 | -2,146 | -1,578 | -1,387 |
Short-Term Debt Issued | 1,578 | 278.61 | 499.94 | - | 2,723 |
Long-Term Debt Issued | 1,064 | 1,000 | - | - | - |
Total Debt Issued | 2,642 | 1,279 | 499.94 | - | 2,723 |
Short-Term Debt Repaid | - | - | - | -1,243 | - |
Long-Term Debt Repaid | -186.82 | -62 | -49.3 | - | - |
Total Debt Repaid | -186.82 | -62 | -49.3 | -1,243 | - |
Net Debt Issued (Repaid) | 2,456 | 1,217 | 450.64 | -1,243 | 2,723 |
Issuance of Common Stock | 0.12 | 0.04 | - | - | - |
Common Dividends Paid | -362.59 | -317.19 | -181.25 | -181.25 | - |
Other Financing Activities | -387.35 | -245.12 | -172.15 | -210.52 | -119.59 |
Financing Cash Flow | 1,706 | 654.35 | 97.24 | -1,635 | 2,604 |
Miscellaneous Cash Flow Adjustments | - | - | 0 | - | - |
Net Cash Flow | 17.97 | -169.01 | 115.14 | -711.52 | 779.41 |
Free Cash Flow | -1,474 | -704.76 | 607.5 | 1,480 | -1,849 |
Free Cash Flow Growth | - | - | -58.95% | - | - |
Free Cash Flow Margin | -8.06% | -3.33% | 3.28% | 7.61% | -15.40% |
Free Cash Flow Per Share | -16.25 | -7.77 | 6.70 | 16.33 | -20.40 |
Cash Interest Paid | - | 245.12 | 172.15 | 210.52 | 3.4 |
Cash Income Tax Paid | - | 645.27 | 569.37 | 623.83 | 211.29 |
Levered Free Cash Flow | -1,623 | -2,176 | -521.96 | 940.76 | -6,998 |
Unlevered Free Cash Flow | -1,330 | -2,008 | -414.37 | 1,072 | -6,995 |
Change in Working Capital | -1,070 | -860.66 | -1,219 | -316.32 | -2,304 |